Boston, MA (PressExposure) April 09, 2012 -- Protein kinases and phosphoserine/threonine-binding domains such as 14-3-3 proteins, FHA domains, Polo-box domains, and BRCT domains function together within signaling networks to control growth factor responses, cell cycle progression, and the response to DNA damage. How signals from these pathways are integrated and processed to control cell phenotypic responses is unclear. To address this, systems biology-based models of DNA damage signaling have been developed where kinase activities, protein phosphorylation, and phosphoprotein-binding events for multiple signaling pathways are quantitatively measured at densely sampled points in time, along with cellular responses such as cell cycle arrest, autophagy, and apoptosis.
The resulting models, built from thousands of signaling measurements and hundreds of cellular response assays, reveals surprisingly paradoxical context-dependent roles for several well-established protein kinase signaling pathways in controlling cell cycle arrest, apoptosis and senescence after DNA damage. Furthermore, the analysis has identified novel treatment approaches that can therapeutically re-wire signaling pathways within tumor cells to dramatically improve tumor cell killing by conventional clinical agents.
GTC's 7th Annual Protein Kinases in Drug Discovery Conference will provide a broad overview of the role kinases play in various types of cancer as well as introduce several novel kinases and inhibitor candidates.
The sessions for the 2012 agenda include 1). Overcoming Challenges in Kinase Drug Development 2). Trends in Drug Design - Structure/Selectivity/Pathway/Epigenetics 3). Oncology Kinases & Inhibitor Candidates 4). Other Kinases & Inhibitor Candidates.
The top companies and experts in the field of Protein Kinases will come together to discuss the latest discoveries. Companies include ArQule, Avila, Beactica AB, Amgen, Bristol-Myers-Squibb, Eli Lilly, Pfizer, Roche, Merck and more!
Keynote & Featured Speakers Include:
Michael Yaffe, Professor, Biology & Biological Engineering, Massachusetts Institute of Technology
Nathanael Gray, Principal Investigator, Biological Chemistry & Molecular Pharmacology, Dana Farber Cancer Institute
Craig C Mello, Nobel Laureate & Distinguished Professor, Molecular Medicine, University of Massachusetts Medical School; HHMI
George Church, Professor, Genetics; Director, Center for Computational Genetics, Harvard Medical School
Steven Burrill, Chief Executive Officer, Burrill & Company
This conference is part of the Omics Evolution Summit which consists of five other conferences:
- 2nd Genomic & Proteomic Drug Discovery
- 2nd Next Generation Sequencing
- Genome-wide Partnering and Dealmaking
- 2nd Epigentics in Drug Discovery
- 3rd RNAi Research and Development
For more information, please visit http://www.gtcbio.com